ERBB2 and breast carcinoma: We believe the ability of dinaciclib to rationally combine with HER2 inhibitors to induce apoptosis could therefore overcome the lack of efficacy HER2 inhibitors in HER2-amplified breast cancers display, providing a targeted therapy combination strategy that could potentially eliminate the need for chemotherapy.